SequelSEC

Edgewise Therapeutics, Inc. EWTX

Pharmaceutical Preparations · CIK 0001710072 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$191.41M
Fiscal year ended 2025-12-31
Free cash flow
-$144.07M
Fiscal year ended 2025-12-31

Edgewise Therapeutics, Inc. (EWTX) reported net income of -$167.80M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Edgewise Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Edgewise Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$191.41M-$158.83M-$114.36M-$71.66M-$43.22M-$17.19M
Net income-$167.80M-$133.81M-$100.16M-$67.64M-$42.81M-$17.12M
Research & development$151.39M$126.97M$90.90M$54.03M$32.19M$14.98M
Weighted-average diluted sharesshares 102.93Mshares 92.41Mshares 63.72Mshares 53.59Mshares 37.53MUnavailable
Pretax income-$167.80M-$133.80M-$100.20MUnavailableUnavailableUnavailable
Income tax expense$4.00K$3.00K$4.00K$0$0Unavailable
Diluted EPS$-1.63$-1.45$-1.57$-1.26$-1.14$-23.17
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$40.02M$31.87M$23.45M$17.63M$11.03M$2.21M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Edgewise Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$61.15M$41.67M$86.10M$21.99M$15.57M$104.92M
Total assets$552.60M$486.82M$340.04M$367.10M$285.23M$131.14M
Current assets$543.38M$475.48M$327.00M$357.00M$283.77M$129.64M
Total liabilities$30.35M$27.60M$21.20M$20.38M$10.85M$4.34M
Current liabilities$27.37M$23.86M$16.77M$16.58M$10.52M$4.34M
Total equity incl. NCI$522.26M$459.22M$318.83M$346.72M$274.38M-$33.42M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$160.21M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.01M$5.58M$4.02M$6.10M$3.84M$1.58M

Cash flow

Edgewise Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$143.82M-$109.03M-$91.95M-$52.64M-$33.51M-$14.63M
Capital expenditures$256.00K$1.31M$5.74M$5.55M$668.00K$203.00K
Investing cash flow-$32.79M-$184.66M$102.89M-$70.58M-$242.23M-$24.38M
Financing cash flow$196.09M$249.25M$53.17M$129.64M$186.38M$120.28M
Net change in cash$19.48M-$44.43M$64.10M$6.43M-$89.35M$81.26M
Stock-based compensation$34.75M$24.71M$17.56M$10.92M$4.40M$354.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Edgewise Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$144.07M-$110.34M-$97.69M-$58.18M-$34.18M-$14.84M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio19.85x19.93x19.50x21.53x26.97x29.86x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EWTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.